Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

CMV-NLS-AcrIIA4 Citations (2)

Originally described in: Engineered anti-CRISPR proteins for optogenetic control of CRISPR-Cas9.
Bubeck F, Hoffmann MD, Harteveld Z, Aschenbrenner S, Bietz A, Waldhauer MC, Borner K, Fakhiri J, Schmelas C, Dietz L, Grimm D, Correia BE, Eils R, Niopek D Nat Methods. 2018 Oct 30. pii: 10.1038/s41592-018-0178-9. doi: 10.1038/s41592-018-0178-9.
PubMed Journal

Articles Citing CMV-NLS-AcrIIA4

Articles
A Chemical Toolbox for Labeling and Degrading Engineered Cas Proteins. Gama-Brambila RA, Chen J, Dabiri Y, Tascher G, Nemec V, Munch C, Song G, Knapp S, Cheng X. JACS Au. 2021 May 12;1(6):777-785. doi: 10.1021/jacsau.1c00007. eCollection 2021 Jun 28. PubMed
In vitro genome editing activity of Cas9 in somatic cells after random and transposon-based genomic Cas9 integration. Sollner JH, Sake HJ, Frenzel A, Lechler R, Herrmann D, Fuchs W, Petersen B. PLoS One. 2022 Dec 30;17(12):e0279123. doi: 10.1371/journal.pone.0279123. eCollection 2022. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.